Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
European Journal of Breast Health|April 9, 2026
Implementing Standardized Ordering Pathways in a Breast Cancer Multidisciplinary Clinic Lifespan Cancer Institute, Providence RIFrancesca Rothell, Ann-Marie Galvin, Mary Anne Fenton
Current Oncology (Toronto, Ont.)|December 22, 2023
Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future RolesMary Anne Fenton, Paolo Tarantino, Stephanie L Graff
American Journal of Clinical Oncology|April 23, 2024
Fulfilling the Role of a Parent While Undergoing Treatment for Cancer: A Review of the Literature and the Potential Impact of Childcare Support on Cancer OutcomesKang Woo Kim, Mary Lopresti, Stephanie L Graff, et al.
Human Pathology|November 8, 2011
Total Survivin and acetylated Survivin correlate with distinct molecular subtypes of breast cancerEvgeny Yakirevich, Ayman Samkari, Michael P Holloway, et al.
BMC Cancer|April 20, 2016
Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancerAlexander S Brodsky, Jinjun Xiong, Dongfang Yang, et al.
Journal of Women'S Health (2002)|November 27, 2023
Evaluating Patient Experience in a Multidisciplinary Breast Cancer Clinic: A Prospective StudyStephanie L Graff, Julie Principe, Anne Marie Galvin, et al.
BMC Cancer|November 3, 2019
Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancerChaohui Lisa Zhao, Kamaljeet Singh, Alexander S Brodsky, et al.
Clinical Breast Cancer|February 19, 2020
New Cardiac Abnormalities After Radiotherapy in Breast Cancer Patients Treated With TrastuzumabElana Nack, Paul P Koffer, Charles S Blumberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group StudyWilliam M Sikov, Don S Dizon, Rochelle Strenger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2016
Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast CancerVinay Varadan, Hannah Gilmore, Kristy L S Miskimen, et al.
Pageof 2